Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen

Andrew G. Diamos, Dalia Larios, Lauren Brown, Jacquelyn Kilbourne, Hyun Soon Kim, Divyasha Saxena, Kenneth E. Palmer, Hugh Mason

Research output: Contribution to journalArticle

Abstract

Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers directed against HPV L2 (>1,000,000) that correlated with virus neutralization. These data indicate a novel immune response synergy upon co-delivery of VLP and RIC platforms, a strategy that can be adapted generally for many different antigens.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalVaccine
Volume37
Issue number1
DOIs
StatePublished - Jan 3 2019

Fingerprint

antigen-antibody complex
virus-like particles
Papillomaviridae
Antigen-Antibody Complex
Virion
Vaccines
vaccines
antigens
Antigens
Papillomavirus Vaccines
Capsid Proteins
plant source protein
Recombinant Proteins
burden of disease
Hepatitis B virus
hepatitis B
Immunoglobulins
neutralization tests
coat proteins
recombinant proteins

Keywords

  • Human papillomavirus
  • Minor capsid protein
  • Recombinant immune complex
  • Vaccine
  • Virus-like particle

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen. / Diamos, Andrew G.; Larios, Dalia; Brown, Lauren; Kilbourne, Jacquelyn; Kim, Hyun Soon; Saxena, Divyasha; Palmer, Kenneth E.; Mason, Hugh.

In: Vaccine, Vol. 37, No. 1, 03.01.2019, p. 137-144.

Research output: Contribution to journalArticle

Diamos, Andrew G. ; Larios, Dalia ; Brown, Lauren ; Kilbourne, Jacquelyn ; Kim, Hyun Soon ; Saxena, Divyasha ; Palmer, Kenneth E. ; Mason, Hugh. / Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen. In: Vaccine. 2019 ; Vol. 37, No. 1. pp. 137-144.
@article{2f9192cef6da421ba8498df83588e500,
title = "Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen",
abstract = "Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers directed against HPV L2 (>1,000,000) that correlated with virus neutralization. These data indicate a novel immune response synergy upon co-delivery of VLP and RIC platforms, a strategy that can be adapted generally for many different antigens.",
keywords = "Human papillomavirus, Minor capsid protein, Recombinant immune complex, Vaccine, Virus-like particle",
author = "Diamos, {Andrew G.} and Dalia Larios and Lauren Brown and Jacquelyn Kilbourne and Kim, {Hyun Soon} and Divyasha Saxena and Palmer, {Kenneth E.} and Hugh Mason",
year = "2019",
month = "1",
day = "3",
doi = "10.1016/j.vaccine.2018.11.021",
language = "English (US)",
volume = "37",
pages = "137--144",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen

AU - Diamos, Andrew G.

AU - Larios, Dalia

AU - Brown, Lauren

AU - Kilbourne, Jacquelyn

AU - Kim, Hyun Soon

AU - Saxena, Divyasha

AU - Palmer, Kenneth E.

AU - Mason, Hugh

PY - 2019/1/3

Y1 - 2019/1/3

N2 - Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers directed against HPV L2 (>1,000,000) that correlated with virus neutralization. These data indicate a novel immune response synergy upon co-delivery of VLP and RIC platforms, a strategy that can be adapted generally for many different antigens.

AB - Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers directed against HPV L2 (>1,000,000) that correlated with virus neutralization. These data indicate a novel immune response synergy upon co-delivery of VLP and RIC platforms, a strategy that can be adapted generally for many different antigens.

KW - Human papillomavirus

KW - Minor capsid protein

KW - Recombinant immune complex

KW - Vaccine

KW - Virus-like particle

UR - http://www.scopus.com/inward/record.url?scp=85056746462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056746462&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2018.11.021

DO - 10.1016/j.vaccine.2018.11.021

M3 - Article

VL - 37

SP - 137

EP - 144

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -